Christos Chouaid

OncopneumologueProfesseur

Enseignants chercheurs

christos.chouaid@chicreteil.fr

Description

Pneumologue, spécialiste en oncologie thoracique et diplômé en Santé publique, Christos Chouaid est Professeur d’université à Paris XII, Créteil. Il est titulaire d’une thèse de Sciences en Santé Publique, obtenue à Paris VI. Il coordonne le GFPC (Groupe de Pneumo Cancérologie Clinique), un réseau de recherche académique regroupant une cinquantaine de centres spécialisés en France.

Il est particulièrement impliqué dans la recherche clinique sur données en vie réelle et a acquis une expertise dans le domaine de l’analyse médico-économique en oncologie thoracique reconnue au niveau nationale et internationale. Il est membre de plusieurs sociétés savantes, expert pour plus de 20 revues scientifiques dans le domaine de l’oncologie thoracique, des maladies respiratoires et de la médico-économie. Il est signataire de plus de 250 manuscrits indexés Medline.

Il est par ailleurs secrétaire générale de la Fondation du Souffle et président du Comité Nationale de lutte contre les Maladies Respiratoires, 2 organismes associatifs qui ont vocation a améliorer l’information sur les maladies respiratoires au niveau de la population générale.

Publications

2021

Bylicki O, Rivière F, Tournier C, Canoui-Poitrine F, Grassin F, Margery J, Prodel M, Vainchtock A, Assié J-B, Chouaid C. Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care. Clin Lung Cancer. 2021;22(3):e320-e328.

2019

Hurtaud A, Aubin M, Ferrat E, Lebreton J, Paillaud E, Audureau E, Bastuji-Garin S, Chouaid C, Boisnault P, Clerc P, Canoui-Poitrine F. Continuity of care in general practice at cancer diagnosis (COOC-GP study): a national cohort study of 2853 patients. Br J Gen Pract. 2019;69(679):e88-e96.

2018

Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C. Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France. Oncology. 2018;95(6):337-343.
Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot ABenjamin, Monnet I. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer. 2018;116:62-66.
Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz P-E, Revel M-P, Westeel V, Dixmier A, Trédaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria J-C, Friard S, Stern J-B, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani J-M, Alifano M, Chatellier G, Girard P. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018;52(4).
Babey H, Quere G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum J-B, Cornec D, Tison A, Chouaid C. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert Rev Anticancer Ther. 2018;18(10):981-989.
Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenègre A, Chouaid C. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert Rev Anticancer Ther. 2018;18(11):1159-1165.
Vergnenègre A, Chouaid C. Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):519-528.
Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018;124:310-316.
Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaid C. New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. Onco Targets Ther. 2018;11:4051-4064.
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer. 2018;124:298-309.
Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Yahia BBen Hadj, Chouaid C. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). Oncology. 2018;94(1):55-64.
Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Trédaniel J, Cadranel J. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. ERJ Open Res. 2018;4(2).
Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac J-B. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget. 2018;9(9):8253-8262.
Chouaid C, Assié JBaptiste, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JClaude. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer Med. 2018;7(4):1102-1109.
Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazières J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenègre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B. Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients. ERJ Open Res. 2018;4(1).
Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim S-W, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim D-W, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(4):576-584.
Boyer L, Bastuji-Garin S, Chouaid C, Housset B, Le Corvoisier P, Derumeaux G, Boczkowski J, Maitre B, Adnot S, Audureau E. Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach. Sci Rep. 2018;8(1):8569.
Schlemmer F, Boyer L, Soumagne T, Ridoux A, Chouaid C, Maitre B, Lanone S, Adnot S, Audureau E, Boczkowski J. Beclin1 circulating levels and accelerated aging markers in COPD. Cell Death Dis. 2018;9(2):156.
Saboundji K, Auliac J-B, Perol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaid C. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. Target Oncol. 2018;13(4):501-507.
Locher C, Pourel N, Le Caer H, Bérard H, Auliac J-B, Monnet I, Descourt R, Vergnenègre A, Lafay IMartel, Greillier L, Chouaid C. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer. 2018;121:25-29.
Scherpereel A, Durand-Zaleski I, Cotté F-E, Fernandes J, Debieuvre D, Blein C, Gaudin A-F, Tournier C, Vainchtock A, Chauvin P, Souquet P-J, Westeel V, Chouaid C. Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. BMC Cancer. 2018;18(1):1013.
Naccache J-M, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J. Lung cancer and interstitial lung disease: a literature review. J Thorac Dis. 2018;10(6):3829-3844.
Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Do P, Dubos-Arvis C, Chouaid C, Gervais R. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Med. 2018;7(11):5505-5513.
Garassino MChiara, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, Jaime JCorral, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521-536.

2017

Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Levy Y, Lelièvre J-D, Adnot S. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol. 2017;140(6):1754-1757.e6.
Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. J Thorac Oncol. 2017;12(10):1496-1502.
Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E. Cost analysis of adverse events associated with non-small cell lung cancer management in France. Clinicoecon Outcomes Res. 2017;9:443-449.
Chouaid C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A-F, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté F-E, Souquet P-J. Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study). PLoS One. 2017;12(8):e0182798.
Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenègre A, Robinet G, Auliac J-B, Gervais R, Chouaid C. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol. 2017;12(5):563-569.
Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, Janicot H, Vergnenègre A, Auliac JBernard, Chouaid C. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer Ther. 2017;17(11):1033-1043.
Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Bérard H, Audigier-Valette C, Dujon C, Auliac JBernard, Crequit J, Monnet I, Vergnenègre A, Chouaid C. Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis. 2017;9(10):3747-3754.
Auliac J-B, Monnet I, Dubos-Arvis C, Chiappa AMarie, Baize N, Bota S, Vergnenègre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). Target Oncol. 2017;12(6):833-838.
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S. Association between lung cancer somatic mutations and occupational exposure in never-smokers. Eur Respir J. 2017;50(4).
Tordrup D, Chouaid C, Cuijpers P, Dab W, van Dongen JMaria, Espin J, Jönsson B, Léonard C, McDaid D, McKee M, Miguel JPereira, Patel A, Reginster J-Y, Ricciardi W, van Molken MRutten-, Rupel VPrevolnik, Sach T, Sassi F, Waugh N, Bertollini R. PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. Int J Technol Assess Health Care. 2017;33(6):609-619.
Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:655-668.
Toumi M, Motrunich A, Millier A, Rémuzat C, Chouaid C, Falissard B, Aballéa S. Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment. J Mark Access Health Policy. 2017;5(1):1344088.
Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:505-518.

2016

Corre R, Greillier L, Le Caer H, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I, Dansin E, Vergnenègre A, Marcq M, Decroisette C, Auliac J-B, Bota S, Lamy R, Massuti B, Dujon C, Perol M, Daurès J-P, Descourt R, Lena H, Plassot C, Chouaid C. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol. 2016;34(13):1476-83.
Chouaid C, Borget I, Braun E, Bazil M-L, Schaetz D, Rémuzat C, Toumi M. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. Target Oncol. 2016;11(4):515-34.
Atsou K, Créquit P, Chouaid C, Hejblum G. Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. PLoS One. 2016;11(6):e0156514.
Vinas F, Ben Hassen I, Jabot L, Monnet I, Chouaid C. Delays for diagnosis and treatment of lung cancers: a systematic review. Clin Respir J. 2016;10(3):267-71.
Vergnenègre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JMiguel, Paz-Arez L, Chouaid C, Rosell R. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol. 2016;11(6):801-7.
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher J-M. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212-223.
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, Chouaid C. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099-104.
Laforest L, Roche N, Devouassoux G, Belhassen M, Chouaid C, Ginoux M, Van Ganse E. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. Respir Med. 2016;117:33-9.
Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]. Bull Cancer. 2016;103(6):552-60.
Fournel P, Vergnenègre A, Robinet G, Lena H, Gervais R, Le Caer H, Souquet P-J, Chavaillon J-M, Bozonnat M-C, Daurès J-P, Chouaid C, Martel-Lafay I. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. Eur J Cancer. 2016;52:181-7.
Créquit P, Ruppert A-M, Rozensztajn N, Gounant V, Vieira T, Poulot V, Antoine M, Chouaid C, Wislez M, Cadranel J, Lavole A. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Lung Cancer. 2016;96:74-7.
Corre R, Lena H, Vergnenègre A, Chouaid C. Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al. J Clin Oncol. 2016;34(33):4050-4051.

2015

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenègre A, de Marinis F, Meng J, Carpeno Jde Castro, Crott R, Kleman M, Ngoh C. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Rev Anticancer Ther. 2015;15(1):121-8.
Toffart A-C, Dhalluin X, Girard N, Chouaid C, Audigier-Valette C, Duruisseaux M, Mennecier B, Parrot A, Fournel P, Moro-Sibilot D, Timsit J-F. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med. 2015;41(1):164-5.
Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Lung Cancer. 2015;90(3):397-404.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet P-J, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-65.
Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet P-J, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavole A, Mazières J, Toffart A-C, Langlais A, Morin F, Zalcman G. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer. 2015;89(2):139-45.
Gervais R, Le Caer H, Monnet I, Falchero L, Baize N, Olivero G, Thomas P, Bérard H, Auliac JBernard, Chouaid C. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clin Lung Cancer. 2015;16(2):100-5.
Cittée J, Sauteron B, Brossier S, Ferrat E, Attali C, Chouaid C, Housset B. [COPD patient care pathways: points of view of hospital personnel]. Sante Publique. 2015;27(1 Suppl):S177-87.
Cittée J, Sauteron B, Brossier S, Ferrat E, Attali C, Chouaid C, Housset B. [In Process Citation]. Sante Publique. 2015;1 Suppl:177-87.
Chouaid C, Crequit P, Borget I, Vergnenègre A. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. Clinicoecon Outcomes Res. 2015;7:9-15.
Boyer L, Chouaid C, Bastuji-Garin S, Marcos E, Margarit L, Le Corvoisier P, Vervoitte L, Hamidou L, Frih L, Audureau E, Covali-Noroc A, Andujar P, Saakashvili Z, Lino A, Ghaleh B, Hue S, Derumeaux G, Housset B, Dubois-Randé J-L, Boczkowski J, Maitre B, Adnot S. Aging-related systemic manifestations in COPD patients and cigarette smokers. PLoS One. 2015;10(3):e0121539.
Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert A-M, Schott R, Lena H, Clément-Duchêne C, Quantin X, Souquet PJean, Trédaniel J, Moro-Sibilot D, Perol M, Madroszyk A-C, Soria J-C. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res. 2015;21(8):1896-903.
Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol J-L, Legodec J, Vergnenègre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni M-C, Thomas PA. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interact Cardiovasc Thorac Surg. 2015;20(6):783-90.

2014

Chouaid C, Borget I, Vergnenègre A. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?. J Clin Oncol. 2014;32(31):3577.
Borget I, Perol M, Pérol D, Lavole A, Greillier L, Do P, Westeel V, Crequit J, Lena H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenègre A, Zalcman G, Chouaid C. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. BMC Cancer. 2014;14:953.
Lerouge D, Rivière A, Dansin E, Chouaid C, Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, Martin F, Dehette S, Fournel P, Precheur-Agulhon B, Lartigau E, Zalcman G. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 2014;14:231.
Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JBernard, Bérard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenègre A. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014;86(2):170-3.

2013

Vergnenègre A, Hominal S, Tchalla AEdem, Bérard H, Monnet I, Fraboulet G, Baize N, Audigier-Valette C, Robinet G, Oliviero G, Le Caer H, Thomas P, Gérinière L, Mastroianni B, Chouaid C. Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study). Lung Cancer. 2013;82(2):353-7.
Vergnenègre A, Borget I, Chouaid C. Treatment of lung cancer: will financial issues become a criterion of choice?. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):273-5.
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1529-37.
Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim J-H, Ahn M-J, Chella A, Chouaid C, Campbell AK, Barlesi F. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol. 2013;8(11):1409-16.
Prat L, Chouaid C, Kettaneh A, Fardet L. Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review. Lung Cancer. 2013;79(1):91-3.
Perol M, Pérol D, Chouaid C. Reply to N. Singh et al. J Clin Oncol. 2013;31(9):1251-2.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.
Doz M, Chouaid C, Com-Ruelle L, Calvo E, Brosa M, Robert J, Decuypère L, Pribil C, Huerta A, Detournay B. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med. 2013;13:15.
Chouaid C, Le Caer H, Corre R, Crequit J, Locher C, Falchero L, Dujon C, Bérard H, Monnet I, Vergnenègre A. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin Lung Cancer. 2013;14(2):103-7.
Chouaid C, Agulnik J, Goker E, Herder GJM, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PLR. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997-1003.
Bylicki O, Ferlay C, Chouaid C, Lavole A, Barlesi F, Dubos C, Westeel V, Crequit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Perol M. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. J Thorac Oncol. 2013;8(7):906-14.
Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard J-F, Alifano M. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013;145(5):1305-11.